Prosus invested $460 million in French health tech company Alan, valuing the startup at $6.3 billion. The transaction highlights continued investor appetite for private-market healthcare technology assets. The news is positive for Alan and supportive of broader late-stage venture funding sentiment, but is unlikely to move public markets materially.
Prosus invested $460 million in French health tech company Alan, valuing the startup at $6.3 billion. The transaction highlights continued investor appetite for private-market healthcare technology assets. The news is positive for Alan and supportive of broader late-stage venture funding sentiment, but is unlikely to move public markets materially.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
